Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Denali Therapeutics Inc., Axsome Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Denali Therapeutics Inc., Axsome Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Denali Therapeutics Inc., Axsome Therapeutics and Inc.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson’s and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company’s OTV programs also comprise DNL628 targeting tau for Alzheimer’s disease; and DNL422 targeting alpha synuclein for Parkinson’s disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer’s disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Latest Biotechnology and Denali Therapeutics Inc., Axsome Therapeutics, Inc. Stock News

As of September 4, 2026, Denali Therapeutics Inc. had a $3.6 billion market capitalization, compared to the Biotechnology median of $282.4 million. Denali Therapeutics Inc.’s stock is up 34.9% in 2026, down 7.2% in the previous five trading days and up 50.64% in the past year.

Currently, Denali Therapeutics Inc. does not have a price-earnings ratio. Denali Therapeutics Inc.’s trailing 12-month revenue is $3.6 million with a % net profit margin. As of September 4, 2026, Denali Therapeutics Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-2.347 per share for the current fiscal year. Denali Therapeutics Inc. does not currently pay a dividend.

As of September 4, 2026, Axsome Therapeutics, Inc. had a $10.8 billion market cap, putting it in the 78th percentile of all stocks. Axsome Therapeutics, Inc.’s stock is up 13.2% in 2026, up 3.8% in the previous five trading days and up 66.13% in the past year.

Currently, Axsome Therapeutics, Inc. does not have a price-earnings ratio. Axsome Therapeutics, Inc.’s trailing 12-month revenue is $776.6 million with a -24.7% net profit margin. Year-over-year quarterly sales growth most recently was 45.6%. Analysts expect adjusted earnings to reach $-2.637 per share for the current fiscal year. Axsome Therapeutics, Inc. does not currently pay a dividend.

How We Compare Denali Therapeutics Inc., Axsome Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Denali Therapeutics Inc., Axsome Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Denali Therapeutics Inc., Axsome Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
Denali Therapeutics Inc.	DNLI	na
Axsome Therapeutics, Inc.	AXSM	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Denali Therapeutics Inc. does not have a meaningful Value Score. Axsome Therapeutics, Inc. has a Value Score of 3, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Denali Therapeutics Inc., Axsome Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Denali Therapeutics Inc., Axsome Therapeutics or Inc. is the better investment when it comes to value.

Denali Therapeutics Inc., Axsome Therapeutics and Inc.’s Quality Grades

Company	Ticker	Quality
Denali Therapeutics Inc.	DNLI	F
Axsome Therapeutics, Inc.	AXSM	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Denali Therapeutics Inc. has a Quality Score of 3, which is Very Weak. Axsome Therapeutics, Inc. has a Quality Score of 42, which is Average.

The Quality Stock Winner: No Clear Winner

Neither Denali Therapeutics Inc., Axsome Therapeutics or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Denali Therapeutics Inc., Axsome Therapeutics or Inc. is the better investment when it comes to quality.

Denali Therapeutics Inc., Axsome Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Denali Therapeutics Inc.	DNLI	D
Axsome Therapeutics, Inc.	AXSM	F

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Denali Therapeutics Inc. has a Earnings Estimate Score of 40, which is Negative. Axsome Therapeutics, Inc. has a Earnings Estimate Score of 12, which is Very Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Denali Therapeutics Inc., Axsome Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Denali Therapeutics Inc., Axsome Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other Denali Therapeutics Inc., Axsome Therapeutics and Inc. Grades

In addition to Value, Estimate Revisions and Quality, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Denali Therapeutics Inc., Axsome Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Denali Therapeutics Inc., Axsome Therapeutics or Inc. Stock?

Overall, Denali Therapeutics Inc. stock has a Value Score of , Estimate Revisions Score of 40 and Quality Score of 3.

Axsome Therapeutics, Inc. stock has a Value Score of 3, Estimate Revisions Score of 12 and Quality Score of 42.

Comparing Denali Therapeutics Inc., Axsome Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.